Pathogenic mutations in the OTOF gene cause autosomal recessive hearing loss (DFNB9),
one of the most common forms of auditory neuropathy. There is no biological treatment for …

The atypical vesicular glutamate transporter type 3 (VGLUT3) is expressed by
subpopulations of neurons using acetylcholine, GABA, or serotonin as neurotransmitters. In …

Approximately 3 in 1000 children in the US under 4 years of age are affected by hearing
loss. Currently, cochlear implants represent the only line of treatment for patients with severe …

A recent study published in Molecular Therapy Nucleic Acids has demonstrated the efficacy
of a tissue-specific gene therapy in a model of autosomal recessive hearing loss 9 …

Glutamate is the principal excitatory neurotransmitter in the mammalian central nervous
system (CNS). Glutamate is first synthesized in the cytoplasm of presynaptic terminals before …

Patients with mutations in the TMPRSS3 gene suffer from recessive deafness
DFNB8/DFNB10. For these patients, cochlear implantation is the only treatment option. Poor …

There is growing attention and effort focused on treating the root cause of sensorineural
hearing loss rather than managing associated secondary characteristic features. With recent …

Background Several genes are candidates for treating inner ear diseases. For clinical
applications, minimally invasive approaches to the inner ear are desirable along with …

Noise-induced excitotoxicity is thought to depend on glutamate. However, the excitotoxic
mechanisms are unknown, and the necessity of glutamate for synapse loss or regeneration …

There are a number of genetic diseases that affect the cochlea early in life, which require
normal gene transfer in the early developmental stage to prevent deafness. The delivery of …